Plain-language summary, compiled from the cited regulatory records
Cefixime is an antibacterial drug belonging to the third-generation cephalosporin class [1]. It is approved for treating certain infections in adults and pediatric patients six months of age and older [1].
Approved uses for cefixime include uncomplicated urinary tract infections, otitis media (middle ear infection), pharyngitis and tonsillitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea (cervical/urethral) [1]. The drug is also indicated to help reduce the development of drug-resistant bacteria [1].
In the past 12 months, there have been 268 adverse event reports associated with cefixime [2]. Common adverse event reports include off-label use, drug ineffectiveness, nausea, pyrexia (fever), and vomiting [2]. Cefixime is available under several brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
CAOfficial regulatory label· Adverse reactions· revised March 22, 2025[1]
Clinical Trials:
Five percent (5%) of patients in the clinical trials discontinued therapy because of drug-related adverse reactions. Thirty-six percent of the pediatric patient population experienced at least one adverse reaction (mild 25%, moderate 9%, severe 2%).
Forty-seven percent of the adult patients experienced at least one adverse reaction (mild 24%, moderate 19%, severe 4%). The most commonly seen adverse reactions in the clinical trials of the tablet formulation were gastrointestinal events, which were reported in 37% of all adult patients treated (mild 21%, moderate 13%, severe 3%).
5%), headache 11%, stool changes 12%, nausea 9%, abdominal pain 5%, dyspepsia 3%, flatulence (3%), dizziness (3%) and vomiting (2%). 9%) versus twice a day (8%). These symptoms usually responded to symptomatic therapy or ceased when cefixime tablets was discontinued.
GBUnited Kingdom· MHRA
3 products
Uses
GBOfficial regulatory label· revised May 22, 2026[2]
Suprax is an orally active cephalosporin antibiotic which has marked in vitro bactericidal activity against a wide variety of Gram-positive and Gram- negative organisms. g. otitis media; and other URTI where the causative organism is known or suspected to be resistant to other commonly used antibiotics, or where treatment failure may carry significant risk.
g. bronchitis. g. cystitis, cystourethritis, uncomplicated pyelonephritis. Clinical efficacy has been demonstrated in infections caused by commonly occuring pathogens including Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Proteus mirabilis, Kliebsiella species, Haemophilus influenzae (beta-lactamase positive and negative), Branhamella catarrhalis (beta-lactamase positive and negative) and Enterobacter species.
Suprax is highly stable in the presence of beta-lactamase enzymes. Most strains of enterococci (Streptococcus faecalis, group D Streptococci) and Staphylococci (including coagulase positive and negative strains and meticillin- resistant strains) are resistant to Suprax.
USUnited States· FDA
1 product
Uses
USOfficial regulatory label· revised February 14, 2024[3]
5) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs, cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.
1 Uncomplicated Urinary Tract Infections Cefixime for oral suspension is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated urinary tract infections caused by susceptible isolates of Escherichia coli and Proteus mirabilis .
2 Otitis Media Cefixime for oral suspension is indicated in the treatment of adults and pediatric patients six months of age or older with otitis media caused by susceptible isolates of Haemophilus influenzae , Moraxella catarrhalis , and Streptococcus pyogenes.
) Note: For patients with otitis media caused by Streptococcus pneumoniae , overall response was approximately 10% lower for cefixime than for the comparator [see Clinical Studies (14) ]. 3 Pharyngitis and Tonsillitis Cefixime for oral suspension is indicated in the treatment of adults and pediatric patients six months of age or older with pharyngitis and tonsillitis caused by susceptible isolates of Streptococcus pyogenes.
Drug interactions
Known interactions involving Cefixime. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
[1]Health Canada (DPD) · 02432773 · revised March 22, 2025
[2]MHRA (UK) · PL127620684 · revised May 22, 2026
[3]FDA DailyMed · 068e6edd-a5fe-40… · revised February 14, 2024 [PDF]
[4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.
Several patients developed severe diarrhea and/or documented pseudomembranous colitis, and a few required hospitalization. 9% (21/358) of patients. 9% of all patients and no adverse reactions were reported as severe. Individual event rates included diarrhea 1% and loose or frequent stools 1%.
Incidence rates for all other adverse reactions reported for adults in these trials were less than 1%.
Clinical Trial and Post-Market Adverse Drug Reactions:
The following adverse reactions have been observed during clinical trial studies and/or during marketed use.
General disorders and administration site conditions:
Drug fever, face oedema.
Hepatobiliary disorders:
Jaundice (cholestatic and/or hepatocellular).
Page 8 of 29 Immune system disorders:
Serum sickness-like reaction, anaphylactic reactions (urticaria and angioedema).
Infections and infestations:
Vaginitis, candidiasis, pseudomembranous colitis.
Investigations:
Elevations of alanine aminotransferase (ALT or SGPT), aspartate aminotransferase (AST or SGOT), alkaline phosphatase and bilirubin. Elevations in Blood Urea Nitrogen (BUN) or creatinine. Prolongation in prothrombin time.
Nervous system disorders:
Headaches, dizziness, convulsions.
Renal and urinary disorders:
Acute renal failure including tubulointerstitial nephritis.
Reproductive system and breast disorders:
Genital pruritus.
Respiratory, thoracic and mediastinal disorders:
Dyspnea, respiratory distress.
Skin and subcutaneous tissue disorders:
Skin rashes, pruritus, urticaria, toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), bullous skin reactions (erythema multiforme and Stevens-Johnson syndrome). In addition to the adverse reactions listed above which have been observed in patients treated with cefixime tablets the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: superinfection, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage, elevated lactate dehydrogenase (LDH) and pancytopenia.
SYMPTOMS AND TREATMENT OF OVERDOSAGE Activated charcoal may be administered to aid in the removal of unabsorbed drug. General supportive measures are recommended. Page 9 of 29 For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.
No specific antidote exists. General supportive measures are recommended. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis.
DOSAGE AND ADMINISTRATION Adults:
The recommended dose of AURO-CEFIXIME tablets (cefixime) is 400 mg once daily. When necessary, a dose of 200 mg (one-half of a 400 mg tablet) given twice daily may be considered except for urinary tract infections where once daily dosing must be used.
For treatment of uncomplicated gonococcal infections, a single oral dose of 400 mg is recommended. Children weighing more than 50 kg or older than 12 years should be treated with the recommended adult dose.
Duration of Therapy:
Duration of dosage in clinical trials was 10 to 14 days. The duration of treatment should be guided by the patient's clinical and bacteriological response. In the treatment of infections due to Streptococcus pyogenes, a therapeutic dose of AURO- CEFIXIME tablets should be administered for at least 10 days.
Renal Impairment:
AURO-CEFIXIME tablets may be administered in the presence of impaired renal function. Normal dose and schedule may be employed in patients with creatinine clearances of 40 mL/min or greater. Patients whose clearance is between 20 and 40 mL/min should be given 75% of the standard daily dosage.
Patients whose creatinine clearance is less than 20 mL/min should be given 50% of the standard daily dosage. Experience in children with renal impairment is very limited.
NOTE:
Neither hemodialysis, nor peritoneal dialysis remove significant amounts of cefixime from the body.
Page 10 of 29 PHARMACEUTICAL INFORMATION Chemistry:
Trade Name: Proper Name: Chemical Name: AURO-CEFIXIME Cefixime (6R,7R)-7-[[(Z)-2-(2-aminothiazol-4-yl)-2- […]
This is not medical advice. Consult a qualified healthcare professional.
In addition, most strains of Pseudomonas, Bacteriodes fragalis, Listeria monocytogenes and Clostridia are resistant to Suprax.
How to take
GBOfficial regulatory label· revised May 22, 2026[2]
The usual course of treatment is 7 days. This may be continued for up to 14 days if required.
Posology Adults and Children over 10 years or weighing more than 50 kg:
The recommended dose is 200 – 400 mg daily according to the severity of infection, given either as a single dose or in two divided doses.
Children under 10 years:
Suprax Tablets 200 mg are not recommended for use in children under 10 years old. The safety and efficacy of cefixime has not been established in children less than 6 months.
Elderly:
Elderly patients may be given the same dose as recommended for adults. Renal function should be assessed, and dosage should be adjusted in severe renal impairment.
Renal impairment:
Suprax may be administered in the presence of impaired renal function. Normal dose and schedule may be given in patients with creatinine clearances of 20 ml/min or greater. In patients whose creatinine clearance is less than 20 ml/min, it is recommended that a dose of 200 mg once daily should not be exceeded.
The dose and regimen for patients who are maintained on chronic ambulatory peritoneal dialysis or haemodialysis should follow the same recommendation as that for patients with creatinine clearances of less than 20 ml/min. Method for administration For oral administration.
Absorption of Suprax is not significantly modified by the presence of food.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
GBOfficial regulatory label· Adverse reactions· revised May 22, 2026[2]
Suprax is generally well tolerated. The majority of adverse reactions observed in clinical trials were mild and self-limiting in nature. The following adverse reaction (Preferred term# or equivalent) will be considered listed: Blood and lymphatic system disorders: Eosinophilia Hypereosinophilia Agranulocytosis Leucopenia Neutropenia Granulocytopenia Haemolytic anaemia Thrombocytopenia Thrombocytosis Gastrointestinal disorders: Abdominal pain Diarrhoea* Dyspepsia Nausea Vomiting Flatulence Hepatobiliary disorders: Jaundice Infections and infestations: Pseudomembranous colitis Vaginitis Investigations: Aspartate aminotransferase increased Alanine aminotransferase increased Blood bilirubin increased Blood urea increased Blood creatinine increased Nervous system disorders: Dizziness Headache Cases of convulsions have been reported with cephalosporins including cefixime (frequency not known) ** Beta-lactams, including cefixime, have been associated with encephalopathy risk (which may include convulsions, confusion, decreased consciousness, movement disorders), particularly in elderly patients, in patients with severe renal impairment or central nervous system disorders and in case of overdose.
4). 4) General disorders and administrative site conditions: Drug Fever Arthralgia Pyrexia Face oedema Genital pruritus The above mentioned listed adverse reactions have been observed during clinical studies and/or during marketed use.
0) *Diarrhoea has been more commonly associated with higher doses. Some cases of moderate to severe diarrhoea have been reported; this has occasionally warranted cessation of therapy. Suprax should be discontinued if marked diarrhoea occurs.
**Cannot be estimated from available data Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
GBOfficial regulatory label· Warnings and precautions· revised May 22, 2026[2]
Encephalopathy Beta-lactams, including cefixime, have been associated with encephalopathy risk (which may include convulsions, confusion, decreased consciousness, movement disorders), particularly in elderly patients, in patients with severe renal impairment or central nervous system disorders and in case of overdose.
If cefixime-associated encephalopathy is suspected discontinuation should be considered. 9) Severe cutaneous adverse reactions Severe cutaneous adverse reactions (SCARS) including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS) drug rash with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) have been reported in association with cefixime.
Patients should be informed about the signs and symptoms of serious skin manifestations and monitored closely. Treatment should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of skin hypersensitivity.
Suprax should be given with caution to patients who have shown hypersensitivity to other drugs. Hypersensitivity to penicillins As with other cephalosporins, cefixime should be given with caution to patients with a history of hypersensitivity to penicillin, as there is some evidence of partial cross- allergenicity between the penicillins and cephalosporins.
Patients have had severe reactions (including anaphylaxis) to both classes of drugs. If an allergic effect occurs with Suprax, the drug should be discontinued and the patient treated with appropriate agents if necessary. Haemolytic anaemia Drug-induced haemolytic anaemia, including severe cases with a fatal outcome, has been described for cephalosporins (as a class).
The recurrence of haemolytic anaemia after re-administration of cephalosporins in a patient with a history of cephalosporin (including cefixime) –associated haemolytic anaemia has also been reported. Acute renal failure As with other cephalosporins, cefixime may cause acute renal failure including tubulointerstitial nephritis as an underlying pathological condition.
When acute renal failure occurs, cefixime should be discontinued and appropriate therapy and/or measures should be taken. 2). 2). Antibiotic-associated colitis Treatment with broad spectrum antibiotics alters the normal flora of the colon and may permit overgrowth of clostridia.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
GBOfficial regulatory label· Contraindications· revised May 22, 2026[2]
1.
This is not medical advice. Consult a qualified healthcare professional.
(Note: Penicillin is the usual drug of choice in the treatment of Streptococcus pyogenes infections. 4 Acute Exacerbations of Chronic Bronchitis Cefixime for oral suspension is indicated in the treatment of adults and pediatric patients six months of age or older with acute exacerbations of chronic bronchitis caused by susceptible isolates of Streptococcus pneumoniae and Haemophilus influenzae.
5 Uncomplicated Gonorrhea (cervical/urethral) Cefixime for oral suspension is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated gonorrhea (cervical/urethral) caused by susceptible isolates of Neisseria gonorrhoeae (penicillinase-and non-penicillinase-producing isolates).
6 Usage To reduce the development of drug resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs, cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How to take
USOfficial regulatory label· revised February 14, 2024[3]
1 Adults The recommended dose of cefixime is 400 mg daily. This may be given as a 400 mg tablet or capsule daily or the 400 mg tablet may be split and given as one half tablet every 12 hours. For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of 400 mg is recommended.
The capsule and tablet may be administered without regard to food. In the treatment of infections due to Streptococcus pyogenes , a therapeutic dosage of cefixime should be administered for at least 10 days. 2 Pediatric Patients (6 months or older) The recommended dose is 8 mg/kg/day of the suspension.
This may be administered as a single daily dose or may be given in two divided doses, as 4 mg/kg every 12 hours.
Note:
A suggested dose has been determined for each pediatric weight range. Refer to Table 1. Ensure all orders that specify a dose in milliliters include a concentration, because cefixime for oral suspension is available in three different concentrations (100 mg/5 mL, 200 mg/5 mL, and 500 mg/5 mL).
Table 1. Suggested doses for pediatric patients * The preferred concentrations of oral suspension to use are 100 mg/5 mL or 200 mg/5 mL for pediatric patients in these weight ranges. 1 or greater 400 20 10 4 2 tablets of 200 mg Children weighing more than 45 kg or older than 12 years should be treated with the recommended adult dose.
Cefixime chewable tablets must be chewed or crushed before swallowing. Otitis media should be treated with the chewable tablets or suspension. Clinical trials of otitis media were conducted with the chewable tablets or suspension, and the chewable tablets or suspension results in higher peak blood levels than the tablet when administered at the same dose.
3) ]. In the treatment of infections due to Streptococcus pyogenes , a therapeutic dosage of cefixime should be administered for at least 10 days. 3 Renal Impairment Cefixime for oral suspension may be administered in the presence of impaired renal function.
Normal dose and schedule may be employed in patients with creatinine clearances of 60 mL/min or greater. Refer to Table 2 for dose adjustments for adults with renal impairment. Neither hemodialysis nor peritoneal dialysis removes significant amounts of drug from the body.
Table 2. 4 Reconstitution Directions for Oral Suspension Strength Bottle Size Reconstitution Directions 100 mg/5 mL 100 mL To reconstitute, suspend with 70 mL water .
Method:
Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. 5 mL water .
Method:
Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. 100 mg/5 mL and 200 mg/5 mL 50 mL To reconstitute, suspend with 35 mL water .
Method:
Tap the bottle several times to loosen powder contents prior to reconstitution. Add approximately half the total amount of water for reconstitution and shake well. Add the remainder of water and shake well. After reconstitution, the suspension may be kept for 14 days either at room temperature, or under refrigeration, without significant loss of potency.
Keep tightly closed. Shake well before using. Discard unused portion after 14 days.
This is not medical advice. Consult a qualified healthcare professional.
Most-reported reactions to the US regulator (12 mo to June 4, 2026): 268 reports total. [4]
Off Label Use 30
Drug Ineffective 27
Nausea 24
Pyrexia 18
Vomiting 18
Pain 17
Headache 16
Constipation 15
Abdominal Pain 14
Malaise 14
Diarrhoea 13
Colitis 12
Side effects & warnings
USOfficial regulatory label· Adverse reactions· revised February 14, 2024[3]
6 ADVERSE REACTIONS Most common adverse reactions are gastrointestinal such as diarrhea (16%), nausea (7%), loose stools (6%), abdominal pain (3%), dyspepsia (3%), and vomiting. (6) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc.
gov/m edwatch. 1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
S. trials of the tablet formulation were gastrointestinal events, which were reported in 30% of adult patients on either the twice daily or the once daily regimen. S. clinical trials discontinued therapy because of drug-related adverse reactions.
Individual adverse reactions included diarrhea 16%, loose or frequent stools 6%, abdominal pain 3%, nausea 7%, dyspepsia 3%, and flatulence 4%. The incidence of gastrointestinal adverse reactions, including diarrhea and loose stools, in pediatric patients receiving the suspension was comparable to the incidence seen in adult patients receiving tablets.
2 Post-marketing Experience The following adverse reactions have been reported following the post-approval use of cefixime. Incidence rates were less than 1 in 50 (less than 2%). Gastrointestinal Several cases of documented pseudomembranous colitis were identified in clinical trials.
The onset of pseudomembranous colitis symptoms may occur during or after therapy. Hypersensitivity Reactions Anaphylactic/anaphylactoid reactions (including shock and fatalities), skin rashes, urticaria, drug fever, pruritus, angioedema, and facial edema.
Erythema multiforme, Stevens-Johnson syndrome, and serum sickness-like reactions have been reported. Hepatic Transient elevations in SGPT, SGOT, alkaline phosphatase, hepatitis, jaundice. Renal Transient elevations in BUN or creatinine, acute renal failure.
Central Nervous System Headaches, dizziness, seizures. Hemic and Lymphatic System Transient thrombocytopenia, leukopenia, neutropenia, prolongation in prothrombin time, elevated LDH, pancytopenia, agranulocytosis, and eosinophilia. Abnormal Laboratory Tests Hyperbilirubinemia.
Other Adverse Reactions Genital pruritus, vaginitis, candidiasis, toxic epidermal necrolysis. Adverse Reactions Reported for Cephalosporin-class Drugs Allergic reactions, superinfection, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, and colitis.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced [see Dosage and Administration (2) and Overdosage (10) ] . If seizures associated with drug therapy occur, the drug should be discontinued.
Anticonvulsant therapy can be given if clinically indicated.
USOfficial regulatory label· Warnings and precautions· revised February 14, 2024[3]
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions including shock and fatalities have been reported with cefixime. Discontinue use if a reaction occurs. 1) Clostridium difficile associated diarrhea: Evaluate if diarrhea occurs. 1 Hypersensitivity Reactions Anaphylactic/anaphylactoid reactions (including shock and fatalities) have been reported with the use of cefixime.
Before therapy with cefixime is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs. If this product is to be given to penicillin-sensitive patients, caution should be exercised because cross hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy.
If an allergic reaction to cefixime occurs, discontinue the drug. 2 Clostridium difficile -Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefixime, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C.
difficile, and surgical evaluation should be instituted as clinically indicated. 3 Dose Adjustment in Renal Impairment The dose of cefixime should be adjusted in patients with renal impairment as well as those undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD).
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
USOfficial regulatory label· Contraindications· revised February 14, 2024[3]
4 CONTRAINDICATIONS Cefixime for oral suspension is contraindicated in patients with known allergy to cefixime or other cephalosporins. Contraindicated in patients with known allergy to cefixime or other cephalosporins. (4)
This is not medical advice. Consult a qualified healthcare professional.
Studies indicate that a toxin produced by Clostridium difficile is a primary cause of antibiotic-associated diarrhoea. Pseudomembranous colitis is associated with the use of broad-spectrum antibiotics (including macrolides, semi-synthetic penicillins, lincosamides and cephalosporins); it is therefore important to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics.
Symptoms of pseudomembranous colitis may occur during or after antibiotic treatment. Management of pseudomembranous colitis should include sigmoidoscopy, appropriate bacteriologic studies, fluids, electrolytes and protein supplementation.
If the colitis does not improve after the drug has been discontinued, or if the symptoms are severe, oral vancomycin is the drug of choice for antibiotic-associated pseudomembranous colitis produced by C. difficile. Other causes of colitis should be excluded.
Patients on dialysis should be monitored carefully [see Dosage and Administration (2) ] . 4 Coagulation Effects Cephalosporins, including cefixime, may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy.
Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. 5 Development of Drug-Resistant Bacteria Prescribing cefixime in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.